| Primary information |
|---|
| ThPP ID | Th1118 |
| Therapeutic Peptide/Protein Name | Sulodexide |
| Sequence | Non-protein view full sequnce in fasta |
| Functional Classification | IIIc |
| Molecular Weight | 5000-8000 |
| Chemical Formula | N.A. |
| Isoelectric Point | N.A. |
| Hydrophobicity | N.A. |
| Melting Point (℃) | N.A. |
| Half Life | elimination half-life was 11.7 ± 2.0 h by IV route |
| Description | A mixture of glycosaminoglycans (GAGs), composed of dermatan sulfate (DS) and fast moving heparin (FMH). |
| Indication/Disease | For the treatment of thrombosis. Also investigated for use/treatment in diabetic kidney disease, and neuropathy (diabetic). |
| Pharmacodynamics | The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters. Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously. |
| Mechanism of Action | Thrombin inhibition produced by sulodexide is due to the additive effect of its components, namely, heparin cofactor II (HCII) catalysis by dermatan sulfate and antithrombin-III catalysis by fast moving heparin (FMH). |
| Toxicity | N.A. |
| Metabolism | N.A. |
| Absorption | Sulodexide is absorbed into the blood stream after oral dosing, the absorption rate being equivalent, either calculated from the fast-moving heparin fraction or from the dermatan fraction. Bioavailability following IM administration is approximately 90%. |
| Volume of Distribution | N.A. |
| Clearance | N.A. |
| Categories | Antithrombins and Fibrinolytic Agents and Hypoglycemic Agents and Anticoagulants and Hypolipidemic Agents |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | N.A. |
| Target | Heparin cofactor 2,Antithrombin-III |
| Information of corresponding available drug in the market |
|---|
| Brand Name | SULODEXIDE |
| Company | Syntex S.A |
| Brand Discription | Sulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%) |
| Prescribed for | Antithrombotic and antithrombin activity is of great pharmacologic interest and makes sulodexide a suitable drug for the prophylaxis and treatment of arterial and venous peripheral diseases |
| Chemical Name | N.A. |
| Formulation | N.A. |
| Physcial Appearnce | N.A. |
| Route of Administration | N.A. |
| Recommended Dosage | N.A. |
| Contraindication | N.A. |
| Side Effects | N.A. |
| Useful Link | http://www.syntexar.com/usr/archivos/99_Sulodexide%20INN%20English.pdf http://en.wikipedia.org/wiki/Sulodexide |
| PubMed ID | 25413777, 25112845, 24936534, 24936533, 24936532, 24936531, 12818259, 9436179 |
| 3-D Structure | N.A. |